Silence Therapeutics PLC Director/PDMR Shareholding (9678M)
August 03 2017 - 1:02AM
UK Regulatory
TIDMSLN
RNS Number : 9678M
Silence Therapeutics PLC
03 August 2017
Director/PDMR Shareholding
3 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it was advised on 2 August that on
that day Alistair Gray, a Non-Executive Director of the Company
bought 3,848 Ordinary Shares at 129.75p.
Following this purchase, Alistair Gray is interested in 3,848
ordinary shares, 0.01% of the issued share capital of the
Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities (PDMR) / person closely associated
--- ---------------------------------------------------------------
a) Name Alistair Gray
--- --------------------- ----------------------------------------
2. Reason for the notification
--- ---------------------------------------------------------------
a) Position / PDMR - Non-Executive Director
status
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
--- --------------------- ----------------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Silence Therapeutics plc
--- --------------------- ----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ---------------------------------------------------------------
a) Description Ordinary Shares in Silence Therapeutics
of the financial plc
instrument,
type of instrument
Identification ISIN for Silence Therapeutics plc
code Ordinary Shares:
GB00B9GTXM62
--- --------------------- ----------------------------------------
b) Nature of the Purchase of Ordinary Shares in
transaction Silence Therapeutics plc
--- --------------------- ----------------------------------------
c) Prices(a) and Price Volume
volume(s) -------- -------
129.75p 3,848
-------- -------
--- --------------------- ----------------------------------------
d) Aggregated
information 3,848 Ordinary Shares
- Aggregated GBP4,993
volume
- Price
--- --------------------- ----------------------------------------
e) Date of the 2 August 2017
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- --------------------- ----------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive Officer 3457 6900
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDDGDICSGBGRD
(END) Dow Jones Newswires
August 03, 2017 02:02 ET (06:02 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024